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Purpose: The value of total transurethral resection of prostate cancer (TURPC) as an alternative therapy was first recognized by 
Hans J. Reuter. Thus, we conducted the study of prospectively collected data to verify total TURPC as an alternative therapy for-
localized prostate cancer.
Methods: From January 2008 to July 2011, 14 patients with a mean age of 76.1 years (range, 66 to 89 years) with clinically local-
ized prostate cancer were treated by prostatic resection by the corresponding author with curative intention.
Results: The mean duration of TURPC was 51.7 minutes (range, 30 to 120 minutes) and the mean amount of prostatic tissue 
resected was 21.2 g (range, 5 to 66 g). An intra- and/or postoperative blood transfusion was necessary in 2 cases. Hyponatremia 
was found in 7 patients. Six months after TURPC, 3 cases of grade 1 and 1 case of grade 2 incontinence were observed. Three 
patients in the high-risk group did not achieve a prostate specific antigen (PSA) nadir of ≤0.2 ng/mL. PSA recurrence occurred 
in one case in our series. Newly developed lymph node or distant metastases were not observed during the follow-up period.
Conclusions: According to our results, transurethral resection for prostate cancer can be performed with reasonable oncologi-
cal results. The PSA nadir levels, and rates of biochemical failure and postoperative complications, including incontinence, were 
comparable with the published results for other procedures. TURPC is also inexpensive and non-invasive, and requires short 
hospitalization and a short surgical time without vesicourethral anastomosis.
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INTRODUCTION
The “gold standard” of prostate cancer treatment is now open, 
laparoscopic, or robot assisted laparoscopic prostatectomy with 
seminal vesiculectomy, and if indicated, staging lymphadenec-
tomy. However, these procedures are not suitable for all patients 
due to several factors, including their high surgical invasiveness, 
risk for aged patients and those with comorbidities, and expense. 
Several alternative treatments, such as high-intensity focused 
ultrasound (HIFU), transurethral microwave thermotherapy, 
cryotherapy, and brachytherapy have been developed. However, 
the existence of a satisfactory alternative method with the po-
tential to achieve complete cancer control was not conclusively 
proven prior to this study [1-7].
  As with open, laparoscopic, or robot assisted laparoscopic 
prostatectomy, a complete resection of the prostate gland in-
cluding cancerous tissues can be achieved using total transure-
thral resection of prostate cancer (TURPC) as an alternative 
therapy was first recognized by Hans J. Reuter. This can be 
complemented by simultaneous laparoscopic staging lymphad-
enectomy and seminal vesiculectomy. Thus, we conducted this 
study to verify total TURPC with related complications as an 
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alternative therapy for localized prostate cancer.
MATERIALS AND METHODS
The study began in January 2008 and ended in July 2011, ap-
proved by Institutional Review Board. A total of 14 patients with 
a mean age of 76.1 years (range, 66 to 89 years) treated by TUR-
PC were included in this study. Neoadjuvant hormonal therapy 
was administered in 5 cases to reduce total prostate volume for 
a shorter operating time. The patients included in this study had 
proven localized prostate cancer of clinical stage T1–T3a by 
2002 American Joint Committee on Cancer tumor, node, me-
tastasis stage, based on histological analysis, preoperative stag-
ing by digital rectal examination, International Prostate Symp-
tom Score, maximal flow rate, transrectal ultrasound, prostate-
specific antigen (PSA) levels, bone scan, abdomen and pelvic 
computed tomography (CT), and chest X-ray. Preoperatively 
detected metastases or treatment by radiotherapy resulted in 
exclusion from the study. This is a pilot study conducted for the 
first time in Korea. Therefore, most of the patients were aged 
over 70 years with or without comorbidity, and thus were not 
suitable candidates for conventional radical prostatectomy. The 
patients were stratified into the following 3 risk groups: low risk 
(clinical stage, T1a–T2a; preoperative PSA level, ≤10 ng/mL; 
and biopsy Gleason score, ≤6), intermediate risk (clinical stage, 
T2b–T2c; preoperative PSA level, 10 to 20 ng/mL; and biopsy 
Gleason score, 7), and high risk (clinical stage, T3a; preopera-
tive PSA level, >20 ng/mL; or biopsy Gleason score, 8 to 10) 
[8].
  We administered prophylactic antibiotics by intravenous in-
jection 30 minutes before surgery. All patients were operated on 
under spinal or epidural anesthesia. Irrigating fluid level did not 
exceed 60 cm above the symphysis of the patient in the lithoto-
my position. Five patients had been receiving neoadjuvant hor-
monal treatment with bicalutamide and luteinizing hormone 
releasing hormone. Monopolar transurethral resection of pros-
tate (TURP) was performed with a 26-Fr continuous flow re-
sectoscope (Karl Storz GmbH & Co. KG, Tuttlingen, Germany) 
using Urosol (CJ, Seoul, Korea). The maximum electrical out-
put of the resectoscope was limited to 140 W for cutting and 80 
W for clotting. At the end of the monopolar TURPC, a 22-Fr 
3-way urethral Foley catheter with an inflated 50 mL balloon 
was inserted, and gentle traction was maintained at about 250 g 
for 4 hours. Continuous saline irrigation was performed until 
the urine draining from the urethral Foley catheter became 
clear in the absence of irrigation. Patients were usually dis-
charged on the second postoperative day. The transurethral 
catheter was removed on the seventh postoperative day in our 
outpatient department.
  Follow-up assessments, with serum PSA testing, rectal ex-
amination, and transrectal ultrasound, were given every 3 
months in the first and second year, then every 6 months with 
CT and bone scans once a year for the first 5 years. Subsequent 
follow-up visits took place once a year.
RESULTS
The 14 patients undergoing total TURPC were aged 66 to 89 
years (mean age, 76.1 years). The mean duration of TURPC was 
51.7 minutes (range, 30 to 120 minutes), and the mean amount 
of resected prostatic tissue was 21.2 g (range, 5 to 66 g). The 
number of patients in each risk group, based on pretreatment 
PSA level, biopsy Gleason score, and clinical stage (Table 1), 
were as follows: low risk, 1; intermediate risk, 6; and high risk, 7.
  Perioperative complications are listed in Table 2. An intra-
and/or postoperative blood transfusion was necessary in 2 cas-
es. Endoscopic examination for bleeding was not required. 
There was no need in any of the cases to perform open surgery 
due to complications of the total TURPC. Hyponatremia was 
found in 7 patients. Bladder neck contracture requiring sound 
dilatation occurred in 1 case. Incontinence was classified into 3 
grades according to the Stamey scale. Six months after TURPC, 
3 cases of grade 1, 1 case of grade 2, and 0 cases of grade 3 in-
continence were observed.
Table 1. Perioperative characteristics of patients
Variable Value
No. of cases 14
Mean age (yr) 76.1
Mean follow-up (mo) 17.9
Low risk 1 (7.1%)
Intermediate risk 6 (42.9%)
High risk 7 (50%)
Very high risk 0 (0%)
Prostate weight (g) by TRUS  
(transitional zone/total)
27.1/51.9
Average mass of tissue resected (g) 21.2
Average surgery time (min) 51.7
TRUS, transrectal ultrasound.224    www.einj.or.kr
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  Three patients in the high-risk group did not achieve a PSA 
nadir of ≤0.2 ng/mL. The Prostate Cancer Guidelines Panel of 
the American Urological Association recommend defining bio-
chemical recurrence after radical prostatectomy as an initial se-
rum PSA level of 0.2 ng/mL or greater, with a second confirma-
tory PSA level greater than 0.2 ng/mL [9]. PSA recurrence oc-
curred in 1 case in our series.
  Postoperatively, 7 patients, including the 3 who did not 
achieve a PSA nadir of ≤0.2 ng/mL and 1 with biochemical re-
currence, received adjuvant hormonal therapy. Newly developed 
lymph node or distant metastases were not observed during the 
follow-up period.
DISCUSSION
Open, laparoscopic, or robot assisted laparoscopic prostatecto-
my is unsuitable for many patients, for reasons including age, 
general high-risk factors, prior prostate surgery, obesity, and so-
cioeconomic factors such as religious restrictions or poverty. 
Analyses of alternative methods such as HIFU, transurethral 
microwave thermotherapy, cryotherapy, and brachytherapy 
have been published, but with follow-up times of <10 years and 
low case numbers. These assessments were therefore of limited 
value. A PSA nadir of 0.2 ng/mL can be achieved or not after 6 
months. This may not necessarily indicate a radical character of 
these process [1-7,10].
  As with conventional surgery, a complete resection of the 
prostate gland, including cancerous tissues, can be achieved us-
ing total TURPC under any circumstances. The boundaries of 
the prostate capsule, the bladder neck, and the membranous 
urethra can be identified with the aid of video image magnifica-
tion (Fig. 1).
  Reuter et al. [11,12] performed a laparoscopic staging lymph-
adenectomy in patients at potential risk of cancer and a life ex-
pectancy of >10 years. Patients who have tumors in the pre-
served seminal vesicle or lymph nodes may not experience a 
PSA nadir of ≤0.2 ng/mL postoperatively, and will require ad-
juvant hormonal therapy with or without laparoscopic seminal 
vesiculectomy or lymphadenectomy. However, we have only 
given adjuvant hormonal therapy in 3 cases with a PSA nadir 
>0.2 ng/mL because of aged patients, comorbidities and the re-
fusal of invasive intervention.
  For prostate cancer focal therapy, 4 modalities appear to have 
the most clinical promise: HIFU, cryotherapy, radiation thera-
py, and photodynamic therapy [13]. If patients with localized 
prostate cancer are suitable candidates for focal therapy, we can 
choose the partial TURPC as an alternative procedure. In our 
experience, we performed right-side TURPC as a focal therapy 
in a case of prostate cancer confined within the right lateral lobe. 
Impotence and incontinence are the major side effects of surgi-
cal treatment of prostate cancer. This is due to the vulnerability 
of the nerve plexus and blood vessels supplying the periprostat-
ic tissue, sphincter, and penis [14]. Accordingly, the transure-
thral approach to the prostate is optimal because the peripros-
tatic tissue, containing the neurovascular bundles, remains in-
tact. The electrical current through the tissue is limited to 140 
W for cutting and 80 W for clotting. The tissue is coagulated 
and cut without the formation of necrosis and with less depth, 
thus pro  tecting the neurovascular bundle. We reduce the elec-
Table 2. Perioperative complications
Complications Value
Transfusion 2 (14.3)
Revision by hemorrhage 0 (0)
Retroperitoneal fluid leakage 1 (7.1)
Hyponatremia 7 (50.0)
Incontinence 
Grade 1 3 (21.4)
Grade 2 1 (7.1)
Grade 3 0 (0)
Postoperative metastatic spread 0 (0)
Bladder neck contracture 1 (7.1)
Urethral stricture 0 (0)
Values are presented as no. of patients (%).
A
D
B
E
C
Fig. 1. Tissue structures surrounding the resected area. (A) Blad-
der neck fascia, (B) external sphincter fiber, (C) posterior pros-
tatic fascia, (D) anterior prostatic fascia, (E) ejaculatory ducts.www.einj.or.kr    225
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trical current when applying the resectoscope to the external 
sphincter muscle.
  Irrigation is needed to clarify the surgical field, and since the 
cutting is done by electricity, the irrigating fluid should be free 
of electrolytes. However, transurethral resection carries the risk 
of TUR syndrome caused by irrigation fluid absorption. The 
increase in dynamic and static pressure increases the risk of flu-
id absorption, which must be avoided to prevent TUR syn-
drome and the spread of prostate cancer cells [14,15]. Reuter et 
al. reported that the key to circumvent such problems is to use 
low-pressure irrigation with an irrigation fluid level less than 20 
cm, and preferably 10 cm above the pubic region using a supra-
pubic trocar. Thus, the capsule can be resected without being 
limited by the need for a short surgical time or by prostate 
weight; the absorption of fluid through capsular perforations is 
prevented; and blood loss is reduced by a better and more 
spontaneous control of arterial and venous bleeding [11-15]. 
TUR syndrome was defined as a serum sodium level of 125 
mmol/L or less after TURP with 2 or more symptoms or signs 
of TUR syndrome, such as nausea, vomiting, bradycardia, hy-
potension, hypertension, chest pain, mental confusion, anxiety, 
paresthesia, and visual disturbance. TUR syndrome did not oc-
cur, but hyponatremia was seen in 7 cases in our series. This 
was treated easily using intravenous furosemide injection with 
or without 3% NaCl solution. Due to inexperience, we used ir-
rigation fluid at 60 cm above the symphysis of the patient with-
out a suprapubic trocar. This may increase fluid absorption into 
the venous plexus. Our policy was to keep the resection time as 
short as possible and to not exceed 60 minutes. We consider 
that a prostate volume of less than 50 mL, as determined by 
transrectal ultrasound was sufficient to ensure safe, fast opera-
tion of this procedure.
  Reuter et al. [11,12] conducted a second surgical session at 8 
to 12 weeks to reduce the risk of positive margins in the rem-
nants of the prostate, similar to the re-transurethral resection of 
bladder tumor procedure for bladder cancer. In general, local 
recurrences can also be resected with a new biopsy as the pri-
mary option before radiation or antiandrogen therapy. We did 
not have a second surgical session in this series. In 3 cases where 
a PSA nadir of ≤0.2 ng/mL was not achieved until 12 weeks af-
ter the operation, adjuvant hormonal therapy was administered 
because of older age and comorbidity.
  Reuter et al. [11,12] performed pathological staging during 
surgery, taking samples in the following order: the 3 lobes one 
by one, the verumontanum, the 2 dorsal quadrants of the true 
capsule (at 6 to 9 and 3 to 6 of the endoscopic clock), the semi-
nal vesicles, the terminal portion of the vas deferens, the pros-
tatic pedicles at 5 and 7, and the 2 ventral quadrants of the cap-
sule (at 9 to 12/12 to 3 of the endoscopic clock). However, we 
chose not to perform frequent fractional extraction of the tissue 
in order to speed up operation time. Therefore, the exact histo-
logical stages of tumors in this case series could not be shown.
  Incontinence is caused by damage to the nerves and/or is a 
result of a preoperatively existing pelvic floor weakness. A di-
rect violation of the external sphincter muscle is unlikely with 
careful surgery [14,15]. Although the mean age of patients and 
the risk of pelvic floor insufficiency were relatively high, the 
grade 2 incontinence rate 6 months after surgery was only 7.1%. 
No patient complained of nocturnal incontinence. The risk of 
erectile impotence was not investigated in this series. A scarred 
bladder neck is the most common postoperative complication 
[13,14]. It should be treated by early dilatation with a 24-Fr 
sound, or an electrical or laser incision. In addition, the urine is 
alkalinized with citrate to prevent scarring of the bladder neck. 
The prognosis of bladder neck stricture is usually good. In our 
case series, it was treated easily using 24-Fr sound dilatation. A 
PSA nadir of ≤0.2 ng/mL can be achieved in 95% of cases, 
which is proof of the efficacy of total TURPC [11,12]. The 5-year 
PSA recurrence rate was 18% for stage pT2 cancer, and the 10-
year survival rate was 85% for stage pT3. These results are equiv-
alent to those of similar surgery reported in recent studies [16-
30]. PSA recurrence occurred in one case in our series although 
the short follow-up duration. We examined PSA nadir to pre-
dict relapse after TURPC [10]. A PSA nadir of ≤0.2 ng/mL was 
not achieved in 3 cases of the high risk group. Postoperatively, 7 
patients including 3 with a PSA nadir >0.2 ng/mL, and 1 with 
biochemical recurrence received adjuvant hormonal therapy. 
Newly developed lymph node or distant metastasis was not ob-
served during the follow-up period.
  In conclusion, using total TURPC in all 14 cases in this se-
ries, we achieved a complete resection of the prostate gland in-
cluding cancerous tissues, but excluding the seminal vesicle and 
lymph nodes, which was comparable to that achieved using 
other surgical procedures. This is reflected in the PSA nadir, 
which is in the majority of cases below ≤0.2 ng/mL. TURPC 
avoids the typical risks of extraprostatic access, because the 
periprostatic tissue is not severed in order to reach the prostate. 
Therefore, injury to the nerves in the periprostatic tissue can be 
avoided, reducing the risk of impotence and incontinence. 
TURPC is also inexpensive and non-invasive, and requires short 226    www.einj.or.kr
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hospitalization and a short surgical time without vesicourethral 
anastomosis.
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